India has withdrawn licensing exemptions for medicinal products containing more than 12% ethyl alcohol to curb misuse. These medicines now require a prescription and a formal license under the Drugs and Cosmetics Act. The move impacts manufacturers of tinctures and high-alcohol medicinal preparations who must now adhere to stricter distribution and record-keeping rules.
The Indian government has implemented stricter controls on pharmaceutical formulations that contain high concentrations of ethyl alcohol. By withdrawing long-standing licensing exemptions for products with more than 12% ethyl alcohol by volume, regulators are aiming to prevent the diversion of these goods for non-medicinal purposes. This shift affects specific preparations, such as certain tinctures, which were previously excluded from standard licensing requirements under Schedule K of the Drugs Rules, 1945.
Regulatory Shift to Schedule H1
Under the updated framework, any formulation exceeding the 12% alcohol threshold—when sold in quantities larger than 30 ml—is now classified under Schedule H1 of the Drugs Rules. This reclassification carries significant operational changes for the industry. Products under Schedule H1 must be sold exclusively against a valid prescription from a registered medical practitioner. Additionally, manufacturers and distributors are now required to maintain rigorous sales records, ensuring that the supply chain is transparent and that these products reach patients rather than unauthorized users.
Impact on Manufacturers and Supply Chain
Historically, products like ginger and cardamom tinctures leveraged the Schedule K exemption to bypass standard licensing hurdles. With some of these formulations containing alcohol levels as high as 80% to 90%, the government identified a clear risk of misuse. For pharmaceutical companies, this regulatory adjustment means that they must now secure formal licenses under the Drugs and Cosmetics Act, 1940. This will likely increase compliance costs and administrative requirements for smaller players who previously operated under the exemption. The government has framed this as a necessary step to align alcohol-based medicinal products with the standards already applied to Ayurveda, Siddha, and Unani systems, which generally cap alcohol content between 12% and 16%.
Monitoring Compliance and Market Access
The ultimate goal of this policy is to ensure that legitimate therapeutic products remain available while curbing the black-market sale of high-alcohol preparations. Investors should monitor how smaller, unorganized players in the medicinal tincture space adapt to these mandatory licensing and record-keeping costs, as it could lead to market consolidation. The key monitorable for the next few quarters will be the speed at which existing manufacturers transition to the new licensing regime and whether the stricter prescription requirements result in a decline in overall sales volumes for these specific high-alcohol categories.